TW202237616A - 螺旋吡咯烷衍生的化合物、醫藥組合物及其用途 - Google Patents
螺旋吡咯烷衍生的化合物、醫藥組合物及其用途 Download PDFInfo
- Publication number
- TW202237616A TW202237616A TW110143587A TW110143587A TW202237616A TW 202237616 A TW202237616 A TW 202237616A TW 110143587 A TW110143587 A TW 110143587A TW 110143587 A TW110143587 A TW 110143587A TW 202237616 A TW202237616 A TW 202237616A
- Authority
- TW
- Taiwan
- Prior art keywords
- optionally substituted
- compound
- mmol
- pharmaceutically acceptable
- nmr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117170P | 2020-11-23 | 2020-11-23 | |
| US63/117,170 | 2020-11-23 | ||
| US202163142663P | 2021-01-28 | 2021-01-28 | |
| US63/142,663 | 2021-01-28 | ||
| US17/479,244 | 2021-09-20 | ||
| US17/479,530 | 2021-09-20 | ||
| US17/479,244 US11384090B2 (en) | 2020-11-23 | 2021-09-20 | Spiropyrrolidine derived antiviral agents |
| US17/479,530 US11352363B1 (en) | 2020-11-23 | 2021-09-20 | Spiropyrrolidine derived antiviral agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202237616A true TW202237616A (zh) | 2022-10-01 |
Family
ID=78725298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110143587A TW202237616A (zh) | 2020-11-23 | 2021-11-23 | 螺旋吡咯烷衍生的化合物、醫藥組合物及其用途 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4001279A1 (https=) |
| JP (1) | JP2023551174A (https=) |
| KR (1) | KR20230124582A (https=) |
| CN (1) | CN114524821B (https=) |
| AU (1) | AU2021381437C1 (https=) |
| CA (1) | CA3173333A1 (https=) |
| CL (1) | CL2023001476A1 (https=) |
| CO (1) | CO2023008018A2 (https=) |
| IL (1) | IL302991A (https=) |
| MX (1) | MX2023005984A (https=) |
| TW (1) | TW202237616A (https=) |
| UY (1) | UY39529A (https=) |
| WO (1) | WO2022109363A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230124583A (ko) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| JP2024525589A (ja) | 2021-07-09 | 2024-07-12 | アリゴス セラピューティクス インコーポレイテッド | 抗ウイルス化合物 |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| WO2023109926A1 (zh) * | 2021-12-17 | 2023-06-22 | 南京药石科技股份有限公司 | 螺环氧化吲哚类化合物及其用于制备抗病毒蛋白酶抑制剂药物的用途 |
| WO2023137007A1 (en) | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
| JP2025509663A (ja) * | 2022-03-18 | 2025-04-11 | エナンタ ファーマシューティカルズ インコーポレイテッド | 置換スピロオキシインドール誘導体を調製するための方法 |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN116621918B (zh) * | 2022-07-20 | 2023-10-31 | 深圳信立泰药业股份有限公司 | 一种螺环化合物及其制备方法与应用 |
| CN115466189B (zh) * | 2022-09-19 | 2024-08-30 | 安徽普利药业有限公司 | 一种氨基酸及其衍生物的纯化方法 |
| AU2023356620A1 (en) * | 2022-10-06 | 2025-04-24 | Enanta Pharmaceuticals, Inc. | Crystal forms of an anti-sars cov-2 agent |
| CN115894504A (zh) * | 2022-10-21 | 2023-04-04 | 深圳信立泰药业股份有限公司 | 一种冠状病毒3cl蛋白酶抑制剂及其用途 |
| US20240199647A1 (en) * | 2022-11-02 | 2024-06-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2024094152A1 (zh) * | 2022-11-03 | 2024-05-10 | 中国科学院上海药物研究所 | 一类螺环化合物、其制备方法及用途 |
| CN118852175A (zh) * | 2023-01-17 | 2024-10-29 | 深圳信立泰药业股份有限公司 | 一种螺环化合物晶型及其制备方法与应用 |
| CN119139307B (zh) * | 2023-12-29 | 2025-09-23 | 上海柯君医药科技有限公司 | 螺环类化合物在制备3CLpro蛋白酶抑制剂或药物中的用途 |
| CN119930495A (zh) * | 2025-01-22 | 2025-05-06 | 中国科学技术大学先进技术研究院 | 化合物及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| CA2524882A1 (en) | 2003-05-06 | 2004-11-25 | Cytovia, Inc. | Protease inhibitors for coronaviruses and sars-cov and the use thereof |
| EP1623028B1 (en) | 2003-05-13 | 2008-01-02 | Universität zu Lübeck | Crystal structure of human coronavirus 229e main proteinase, and uses thereof for developing sars inhibitors |
| US20060014821A1 (en) | 2003-08-27 | 2006-01-19 | Agouron Pharmaceuticals, Inc. | Inhibitors of SARS 3C like protease |
| US7462594B2 (en) | 2003-12-31 | 2008-12-09 | Taigen Biotechnology Co., Ltd. | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases |
| WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| WO2006061714A2 (en) | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| MY160077A (en) * | 2011-01-21 | 2017-02-15 | Univ Sains Malaysia | Curcumin compounds and their preparations thereof |
| AR086554A1 (es) * | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| CA2850003C (en) | 2011-09-27 | 2020-01-07 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
| US20140349920A1 (en) * | 2012-01-03 | 2014-11-27 | Ruey J. Yu | N-acylpeptide derivatives and their uses |
| EP2844249A4 (en) | 2012-05-02 | 2016-03-09 | Univ Kansas State | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS VIRUZIDES AGAINST 3C OR 3C LIKE PROTEASES OF PICORNIVERS, CALICIVIRES AND CORONA VIRUSES |
| WO2017035409A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017222935A1 (en) * | 2016-06-20 | 2017-12-28 | Kansas State University Research Foundation | Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses |
| WO2018023054A1 (en) | 2016-07-28 | 2018-02-01 | Kansas State University Research Foundation | Protease transition state inhibitor prodrugs |
| UY37381A (es) | 2016-08-30 | 2018-03-23 | Glaxosmithkline Ip No 2 Ltd | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos |
| JP7691691B2 (ja) * | 2020-09-11 | 2025-06-12 | 公立大学法人横浜市立大学 | 新型コロナウイルス感染症の予防又は治療用の食品組成物、医薬品組成物、医薬部外品組成物、化粧品組成物、及び雑貨 |
| KR20230124583A (ko) * | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
-
2021
- 2021-11-22 IL IL302991A patent/IL302991A/en unknown
- 2021-11-22 JP JP2023530325A patent/JP2023551174A/ja active Pending
- 2021-11-22 KR KR1020237020684A patent/KR20230124582A/ko active Pending
- 2021-11-22 EP EP21209522.8A patent/EP4001279A1/en active Pending
- 2021-11-22 WO PCT/US2021/060247 patent/WO2022109363A1/en not_active Ceased
- 2021-11-22 CA CA3173333A patent/CA3173333A1/en active Pending
- 2021-11-22 MX MX2023005984A patent/MX2023005984A/es unknown
- 2021-11-22 UY UY0001039529A patent/UY39529A/es unknown
- 2021-11-22 CN CN202111385187.8A patent/CN114524821B/zh active Active
- 2021-11-22 AU AU2021381437A patent/AU2021381437C1/en active Active
- 2021-11-23 TW TW110143587A patent/TW202237616A/zh unknown
-
2023
- 2023-05-22 CL CL2023001476A patent/CL2023001476A1/es unknown
- 2023-06-20 CO CONC2023/0008018A patent/CO2023008018A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3173333A1 (en) | 2022-05-27 |
| CO2023008018A2 (es) | 2023-07-10 |
| UY39529A (es) | 2022-06-30 |
| CL2023001476A1 (es) | 2023-12-11 |
| WO2022109363A1 (en) | 2022-05-27 |
| AU2021381437B2 (en) | 2025-12-18 |
| JP2023551174A (ja) | 2023-12-07 |
| EP4001279A1 (en) | 2022-05-25 |
| CN114524821B (zh) | 2026-01-02 |
| AU2021381437C1 (en) | 2026-04-02 |
| KR20230124582A (ko) | 2023-08-25 |
| IL302991A (en) | 2023-07-01 |
| AU2021381437A1 (en) | 2023-06-22 |
| AU2021381437A9 (en) | 2024-10-10 |
| CN114524821A (zh) | 2022-05-24 |
| MX2023005984A (es) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114524821B (zh) | 螺旋吡咯烷衍生的抗病毒药物 | |
| JP7795521B2 (ja) | 抗ウイルス剤としての官能化ペプチド | |
| US12540141B2 (en) | Spiropyrrolidine derived antiviral agents | |
| US11339170B1 (en) | Spiropyrrolidine derived antiviral agents | |
| US11352363B1 (en) | Spiropyrrolidine derived antiviral agents | |
| US11384090B2 (en) | Spiropyrrolidine derived antiviral agents | |
| US11912714B2 (en) | Spiropyrrolidine derived antiviral agents | |
| CN116829571A (zh) | 新型螺旋吡咯烷衍生的抗病毒药物 | |
| WO2023091561A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| WO2022235605A1 (en) | Novel macrocyclic antiviral agents | |
| TW202321251A (zh) | 新穎螺環吡咯啶衍生的抗病毒劑 | |
| TW202321252A (zh) | 新穎螺環吡咯啶衍生的抗病毒劑 | |
| CN116547294A (zh) | 作为抗病毒剂的功能化肽 | |
| WO2023107419A1 (en) | Saturated spirocyclics as antiviral agents | |
| WO2023086350A1 (en) | Alkyne-containing antiviral agents | |
| WO2023107417A1 (en) | Heterocyclic antiviral agents | |
| WO2023003610A1 (en) | Novel spiropyrrolidine derived antiviral agents | |
| HK40071048A (en) | Novel spiropyrrolidine derived antiviral agents | |
| EA048496B1 (ru) | Новые противовирусные агенты на основе производных спиропирролидина | |
| HK40096316A (zh) | 作为抗病毒剂的功能化肽 | |
| CN118043045A (zh) | 新型螺吡咯烷衍生的抗病毒药物 | |
| JP2024529476A (ja) | 新規スピロピロリジン誘導抗ウイルス剤 |